Triple

T22690292
Position Surface form Disambiguated ID Type / Status
Subject CDK4 E561032 entity
Predicate substrate P16678 FINISHED
Object RBL2 NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: RBL2 | Statement: [CDK4, substrate, RBL2]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: RBL2
Context triple: [CDK4, substrate, RBL2]
  • A. RBL1
    RBL1 is a tumor suppressor protein of the retinoblastoma family that regulates cell cycle progression by controlling E2F transcription factor activity.
  • B. c-Myc
    c-Myc is a proto-oncogene transcription factor that regulates cell growth, proliferation, and metabolism and is frequently dysregulated in cancer.
  • C. RB1
    RB1 is a tumor suppressor protein that regulates the cell cycle by controlling the transition from G1 to S phase and is frequently inactivated in human cancers.
  • D. Clb3
    Clb3 is a B-type cyclin in budding yeast that partners with the Cdc28 kinase to regulate progression through the cell cycle, particularly during S and G2 phases.
  • E. CDK6
    CDK6 is a cyclin-dependent kinase that regulates cell cycle progression and is a key target in certain cancer therapies.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: RBL2
Target entity description: RBL2 is a tumor suppressor protein of the retinoblastoma family that regulates cell cycle progression by controlling E2F transcription factor activity.
  • A. RBL1
    RBL1 is a tumor suppressor protein of the retinoblastoma family that regulates cell cycle progression by controlling E2F transcription factor activity.
  • B. c-Myc
    c-Myc is a proto-oncogene transcription factor that regulates cell growth, proliferation, and metabolism and is frequently dysregulated in cancer.
  • C. RB1
    RB1 is a tumor suppressor protein that regulates the cell cycle by controlling the transition from G1 to S phase and is frequently inactivated in human cancers.
  • D. Clb3
    Clb3 is a B-type cyclin in budding yeast that partners with the Cdc28 kinase to regulate progression through the cell cycle, particularly during S and G2 phases.
  • E. CDK6
    CDK6 is a cyclin-dependent kinase that regulates cell cycle progression and is a key target in certain cancer therapies.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789a1fd08190bce5fa0babe695d3 completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.